Sign In

John Gordon

Independent Writing and Editing Professional

John Gordon is a highly accomplished professional with a significant background in Immunology, particularly focused on B lymphocytes and their associated malignancies such as lymphoma and leukemia.

His expertise and contributions in the field have been recognized through over 250 published papers and his inclusion in the exclusive group of ISI's 'Most Highly Cited Researchers'.

After his retirement from the University of Birmingham in 2013, where he maintained the prestigious title of Professor Emeritus, John shifted his focus to the dynamic realm of the Birmingham & Oxford based CRO, Celentyx Ltd.

In 2004, John collaborated with Neuropharmacologist Nick Barnes to establish Celentyx Ltd, a leading CRO specializing in Human Immuno-Profiling tailored for the pharmaceutical and biotech industries.

Celentyx's distinctive access to fresh patient material positions them as a key player in advancing the translation of experimental compounds from laboratory settings to clinical applications.

John's professional specialties extend to areas such as immunooncology, IgE-mediated allergies, B-cell-driven autoimmunity, apoptosis, receptor signaling, and neuroimmunology, showcasing his diverse skill set and knowledge base.

His educational journey includes a Ph.D. in Immunology/Hematology from the University of Southampton, a B.Sc. in Chemistry from the University of Birmingham, and fellowships at esteemed institutions like the Karolinska Institutet and the University of Cambridge.

Throughout his career, John has held key roles in various organizations, including his tenure as the VP of Scientific Affairs, Co-Founder, and Director at Celentyx Ltd, highlighting his leadership and entrepreneurial acumen.

Additionally, he has contributed to the academic community through positions such as Raine Visiting Professor at the University of Western Australia and Visiting Scientist at the DNAX Research Institute.

Highlights

Sep 2 · linkedin

#IgE | Time to "UNSWEETEN" the #TherapeuticAntibody Pill 🤔 | Systematic mutational analysis reveals essential role of N275 in IgE #stability | No "Sugar-Coating" of Surprise Findings from Achim Doerner & Co. in new online study |

Therapeutic antibodies have predominantly been IgG-based. However, the ongoing clinical trial of MOv18 IgE has highlighted the potential of using IgE antibodies in cancer therapy. While extensive studies targeting IgG glycosylation resulted in a rational basis for the development of enhanced biotherapeutics, IgE glycosylation remains an area with limited analyses.

Previous studies on the role of IgE glycosylation present conflicting data with one study emphasizing the importance of N275 and T277 residues for FcεRI binding whereas another asserts the nonsignificance of IgE glycosylation in receptor interaction. While existing literature underscores the significance of glycans at the N275 position for binding to FcεR1 receptor and initiation of anaphylaxis, the role of other IgE glycosylation sites in folding or receptor binding remains elusive.

This study* from Shikha K, Sanjay Ghosh, et al systematically investigates the functional significance of N-linked glycosylation sites in the heavy chain of IgE which validates the pivotal role of N275 residue in IgE secretion and stability. Replacement of this asparagine to non-amine group moieties does not affect IgE function in vitro, yet substitution with aspartic acid compromises antibody yield. The deglycosylated IgE variant exhibits superior efficacy, challenging the conventional importance of glycosylation for effector function.

In summary, this study unveils an intricate relationship between N-glycosylation sites and the structural–functional dynamics of IgE antibodies. Furthermore, it offers novel insights into the IgE scaffold, paving the way for the development of more effective and stable IgE-based therapeutics.

*https://lnkd.in/e5yU6Mnb; (full text available at https://lnkd.in/eztiBM3R)

Celentyx Ltd #immunooncology www.celentyx.com

Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady

Dr Neil Bodie

FIGURE | Upper: Schematic diagram showing the engineered IgE variants | Lower: Mechanism of cytotoxicity mediated by MOv18 IgE (taken from Sophia N Karagiannis & Co. https://lnkd.in/eUnGRRKh) |

Aug 31 · linkedin

#NaCl in the #TumorMicroEnvironment enhances the Metabolic Fitness & Cytotoxicity of #Tcells | 'Cheap-as-Chips' ex vivo conditioning for #CARTcells | Breaking Nature #Immunology Study is truly "Worth Its #Salt" 👏 | #TME |

The efficacy of antitumor immunity is associated with the metabolic state of cytotoxic T cells, which is sensitive to the tumor microenvironment. Whether ionic signals affect adaptive antitumor immune responses is unclear.

In the present study*, a team led by Christina Zielinski show that there is an enrichment of sodium in solid tumors from patients with breast cancer. Sodium chloride (NaCl) enhances the activation state and effector functions of human CD8+ T cells, which is associated with enhanced metabolic fitness. These NaCl-induced effects translate into increased tumor cell killing in vitro and in vivo.

Mechanistically, NaCl-induced changes in CD8+ T cells are linked to sodium-induced upregulation of Na+/K+-ATPase activity, followed by membrane hyperpolarization, which magnifies the electromotive force for T cell receptor (TCR)-induced calcium influx and downstream TCR signaling.

It is therefore proposed that NaCl is a positive regulator of acute antitumor immunity that might be modulated for ex vivo conditioning of therapeutic T cells, such as CAR T cells.

*https://lnkd.in/ehiuAi7s

Celentyx Ltd #immunooncology www.celentyx.com

Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady

FIGURE | Overview of molecular mechanism of NaCl-induced T cell hyperactivation |

J
Add to my network

Location

North Salem, New York, United States